Citizens Jmp Issues Positive Forecast for Benitec Biopharma (NASDAQ:BNTC) Stock Price

Benitec Biopharma (NASDAQ:BNTC) had its target price boosted by analysts at Citizens Jmp from $20.00 to $22.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price objective suggests a potential upside of 38.71% from the company’s previous close.

BNTC has been the subject of several other reports. Oppenheimer reiterated an “outperform” rating and issued a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. Zacks Research cut shares of Benitec Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Finally, JMP Securities restated a “market outperform” rating and issued a $20.00 price target on shares of Benitec Biopharma in a research report on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.33.

Benitec Biopharma Stock Performance

BNTC opened at $15.86 on Tuesday. The business has a fifty day simple moving average of $14.42 and a 200 day simple moving average of $13.76. The company has a market capitalization of $416.33 million, a PE ratio of -10.79 and a beta of 0.41. Benitec Biopharma has a 1 year low of $9.10 and a 1 year high of $17.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 54.67 and a quick ratio of 54.67.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.18). Research analysts expect that Benitec Biopharma will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors have recently bought and sold shares of the stock. Simplify Asset Management Inc. grew its position in Benitec Biopharma by 13.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 78,725 shares of the biotechnology company’s stock worth $1,105,000 after purchasing an additional 9,552 shares in the last quarter. Bank of America Corp DE boosted its stake in Benitec Biopharma by 2,255.8% during the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,587 shares during the period. Ameriprise Financial Inc. boosted its stake in Benitec Biopharma by 219.4% during the second quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company’s stock valued at $1,286,000 after buying an additional 75,507 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Benitec Biopharma during the second quarter worth about $93,000. Finally, Marshall Wace LLP bought a new position in Benitec Biopharma in the 2nd quarter worth about $503,000. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.